Overuse testing at the patient level
cancer type, tumor, breast cancer
TUMOR, BREAST CANCER
From the 316 patients in the study (137 breast, 67 colorectal, 112 prostate), 111 patients had tests that were identified for review as potential overuse. After excluding non‐cancer‐related tests, 53 patients had at least one cancer‐related test that needed adjudication for overuse. Some patients had multiple tests ordered (e.g., serial tumor markers, tumor markers and CT, tumor markers and PET). Ultimately, 27 patients were determined to have at least one test consistent with overuse. Among the 27 patients with any testing consistent with overuse, 22 were breast cancer patients. A total of 16 breast cancer patients at the community site accounted for all 78 tumor marker tests consistent with overuse. By cancer type, breast cancer patients most frequently had at least one test consistent with overuse (22/137, 16%) (Table 